Which Form?
GLP-1 Agonists
Moderate
consensus
Available Forms
- Injectable (subcutaneous, once weekly)
- Oral formulations are in development
- Some clinicians use compounded peptide formulations at lower doses (Attia, Koniver)
Dosage & Timing
Dosage
- Semaglutide: typically starts at 0
- 25mg/week, titrated up to 2
- 4mg/week for weight management
- Tirzepatide: starts at 2
- 5mg/week, titrated up to 15mg/week
- Dosing is individualized by a prescribing physician (Attia)
Timing
- Once-weekly injection
- No specific time-of-day requirement
- Must be combined with strength training and high protein intake (minimum 1g per pound of lean body mass) to mitigate muscle loss (Attia)
Expert Positions
What Each Expert Says
Huberman covers GLP-1 agonists across multiple contexts: hunger neuroscience, peptide therapy, and fat loss protocols. He features Dr. Zachary Knight (UCSF) explaining the mechanism of GLP-1 drugs, their origin from Gila monster venom, and the evolution from short-acting to long-acting forms. He discusses how GLP-1 acts on brain stem and hypothalamic circuits to suppress appetite. In peptide therapy episodes, Dr. Craig Koniver discusses micro-dosing semaglutide and tirzepatide to mitigate side effects. Huberman also frequently mentions yerba mate as a natural GLP-1 stimulator for fat loss.
Unlock Expert Deep Dives
See exactly which form each expert takes, why they chose it, and their reasoning with video citations.
View Full Report